TG4010

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
TG4010
DrugBank Accession Number
DB06584
Background

A bivalent cancer vaccine comprised of a modified vaccinia virus Ankara (MVA) strain encoding human mucin 1 (MUC1) and interleukin-2 (IL-2) with potential immunostimulating and antineoplastic activities. Originally developed for the eradication of smallpox, MVA is a highly attenuated and replication-defective strain incapable of virion assembly and exerts potent immunostimulatory activity against antigens. Vaccination with MVA-MUC1-IL2 vaccine may stimulate the host immune system to mount a humoral and cytotoxic T lymphocyte (CTL) responses against tumor cells expressing MUC1, a tumor associated antigen, resulting in tumor cell lysis. Expression of IL-2 augments the specific CTL response against MUC1 expressing cells. 1

Type
Biotech
Groups
Investigational
Biologic Classification
Vaccines
Other vaccines
Synonyms
  • MVA-Muc1-IL2
External IDs
  • TG 4010
  • TG4010

Pharmacology

Indication

Investigated for use/treatment in breast cancer, renal cell carcinoma, prostate cancer, and lung cancer.

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
TargetActionsOrganism
UMucin-1Not AvailableHumans
UInterleukin-2Not AvailableHumans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbataceptThe therapeutic efficacy of TG4010 can be decreased when used in combination with Abatacept.
AdalimumabThe therapeutic efficacy of TG4010 can be decreased when used in combination with Adalimumab.
AldesleukinThe therapeutic efficacy of TG4010 can be decreased when used in combination with Aldesleukin.
AlefaceptThe therapeutic efficacy of TG4010 can be decreased when used in combination with Alefacept.
AlemtuzumabThe therapeutic efficacy of TG4010 can be decreased when used in combination with Alemtuzumab.
AltretamineThe therapeutic efficacy of TG4010 can be decreased when used in combination with Altretamine.
AmsacrineThe therapeutic efficacy of TG4010 can be decreased when used in combination with Amsacrine.
AnakinraThe therapeutic efficacy of TG4010 can be decreased when used in combination with Anakinra.
Antilymphocyte immunoglobulin (horse)The therapeutic efficacy of TG4010 can be decreased when used in combination with Antilymphocyte immunoglobulin (horse).
Antithymocyte immunoglobulin (rabbit)The therapeutic efficacy of TG4010 can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
Not Available
CAS number
350485-85-7

References

General References
  1. NCI Drug Dictionary: MVA-MUC1-IL2 vaccine [Link]
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2Active Not RecruitingTreatmentAdvanced Non Small Cell Lung Cancer (NSCLC) / Lung Cancer, Nonsmall Cell, Stage I / Nonsmall Cell Lung Cancer, Stage II / Recurrent Non-Small Cell Lung Carcinoma / Stage IIIA Non Small Cell Lung Cancer / Stage IIIB Non Small Cell Lung Cancer1
2Active Not RecruitingTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
2TerminatedTreatmentProstatic Neoplasms1
2, 3CompletedTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
2, 3TerminatedTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
1CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Targets

Drugtargets2
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Transcription cofactor activity
Specific Function
The alpha subunit has cell adhesive properties. Can act both as an adhesion and an anti-adhesion protein. May provide a protective layer on epithelial cells against bacterial and enzyme attack.The ...
Gene Name
MUC1
Uniprot ID
P15941
Uniprot Name
Mucin-1
Molecular Weight
122100.89 Da
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Kinase activator activity
Specific Function
Produced by T-cells in response to antigenic or mitogenic stimulation, this protein is required for T-cell proliferation and other activities crucial to regulation of the immune response. Can stimu...
Gene Name
IL2
Uniprot ID
P60568
Uniprot Name
Interleukin-2
Molecular Weight
17627.52 Da

Drug created on March 19, 2008 16:38 / Updated on June 12, 2020 16:52